FATE Fate Therapeutics Inc Final Profit

Corporate emblem and logo of Fate Therapeutics (FATE)

The value of Fate Therapeutics, Inc. (FATE) is based on an innovative method of using stem cells to combat tumors, with margin efficiency tied to development results. This high-tech sector is not subject to economic cycles, as success here depends on partnerships and clinical trials. This daily price chart of the current market value on GURU.Markets shows a profit at the level of -0.13, confirming the company's status in the field of oncotherapy.

FATE (Fate Therapeutics, Inc.) Net Profit history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company Fate Therapeutics (FATE)

- stock value and consensus price forecast:
Market Price Fate Pharma|FATE - Price Target Chart
- market capitalization data:
Market Value Fate Pharma|FATE - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Fate Therapeutics|FATE - Book Capitalization|Market Cap to Net Assets Ratio fatetherapeutics.com|FATE - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Fate Therapeutics, Inc.|FATE - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Fate Therapeutics Inc|FATE - Company Aggregate Debts|Debts to Book Value Fate Pharma|FATE - Company Long-Term Debts|Current Liabilities Fate Therapeutics|Quick Ratio fatetherapeutics.com
- net income and valuation multiples indicators:
FATE - Net Income
Fundamental valuation:FATE Fate Pharma
Manufactured product of Fate Therapeutics Inc

For Fate Therapeutics, Inc. (FATE), the company's commercial result reflects the monetization dynamics of oncology innovations. This indicator captures daily net profit, serving as an objective measure of current cash flow. The calculation is based on the operational results of each trading day, eliminating reporting time lags. A stable operating environment in the US minimizes external risks, increasing the reliability of this data. Precise profit monitoring helps avoid capital freezes when buying at peaks.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Profit ARAY|SLS: Profit After Tax|Net Profit ACTU (Actuate Therapeutics)|Net Profit Citius Oncology Inc. CTOR|HURA: Net Income|Protara Tx - Profit After Payment of Taxes|WHWK: Net Profit|Company Net Income TScan Therapeutics, Inc. (TCRX)|Net Income CSBR|XBIT: Final Profit|Net Income CVM (CEL-SCI Corporation)|Profit After Payment of Taxes OSTX|Net Profit RADX (Radiopharm Theranostics Limited)|Final Profit ARTV|Adlai Nortye Limited - Net Profit|Company Net Income Veru Inc|Tempest Tx (TPST) - Company Net Income|Xilio Therapeutics - Final Profit|RENB (Renovaro Biosciences) - Net Profit|Net Profit Mural Bio|Company Net Income Kairos Pharma Ltd (KAPA)|OKUR: Profit After Tax|Net Profit GDTC (CytoMed Therapeutics Limited)|Curis Inc. (CRIS) - Company Net Income|APLM: Net Income|THAR - Net Profit|ADVB (advanbiomed.com) - Net Income|GNPX: Profit After Payment of Taxes|CLDI (Calidi Biotherapeutics Inc.) - Net Profit|Sunshine Biopharma Inc. (SBFM) - Net Financial Result|Net Profit XBIO|Net Income salariuspharma.com SLRX|Company Net Income Purple Biotech Ltd. PPBT|Net Financial Result American Oncology Network Inc (AONC)|BGNE: Net Income|Final Profit CKPT (Checkpoint Therapeutics Inc)|ELEV: Net Profit|ICAD - Net Financial Result|Company Net Income Ikena Oncology Inc.|Company Profit NTBL (Notable Labs Ltd)|Net Profit VIRX|Net Income MorphoSys Corporation MOR|NAYA Biosciences - Net Income|Net Financial Result ascentage.com (AAPGV)